Market Place
Sourcing Support
JCR Pharmaceuticals Starts Phase I Trial of JR-441 in MPS IIIA
31 Oct 2024 //
BUSINESSWIRE
JCR Pharmaceuticals Presents Gene Therapy Research at Congress
23 Oct 2024 //
BUSINESSWIRE
JCR Pharmaceuticals To Present At ESGCT 31st Annual Congress
16 Oct 2024 //
BUSINESSWIRE
JCR Pharmaceuticals` Data Presentations At SSIEM Symposium
05 Sep 2024 //
BUSINESSWIRE
JCR Pharmaceuticals Completes Clinical Trial Notification in Japan for JR-441
03 Sep 2024 //
BUSINESSWIRE
JCR Pharmaceuticals Presents Gene Therapy Research At Lysosomal Forum
18 Jul 2024 //
BUSINESSWIRE
MEDIPAL And JCR Complete Clinical Trial Notification For JR-446 In Japan
02 Jul 2024 //
BUSINESSWIRE
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo
19 Mar 2024 //
BUSINESSWIRE
JCR Pharmaceuticals Celebrates Rare Disease Day 2024
29 Feb 2024 //
BUSINESSWIRE
JCR’s Research Presentations at WORLDSymposium™ 2024 Showcase JR-141
14 Feb 2024 //
BUSINESSWIRE
JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024
25 Jan 2024 //
BUSINESSWIRE
JCR Pharma and Takeda Announce Discontinuation of Gene Therapy Collaboration
21 Dec 2023 //
BUSINESSWIRE
U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of MPS IIIA
15 Dec 2023 //
BUSINESSWIRE
Modalis and JCR Pharmaceuticals enter into joint research agreement
12 Dec 2023 //
BUSINESSWIRE
JCR Pharma Announces First Patient Dosed in a Phase I/II Trial of JR-441
10 Nov 2023 //
BUSINESSWIRE
JCR Announces Data from its Global Phase I/II Study of JR-171
29 Sep 2023 //
BUSINESSWIRE
AstraZeneca inks deal with Japanese biotech JCR in CNS indication
04 Apr 2023 //
ENDPTS
JCR Pharmaceuticals Announces License Agreement with Alexion
03 Apr 2023 //
BUSINESSWIRE
JCR Pharmaceuticals’ Presentations at WORLDSymposium 2022 Showcase JR-141
15 Feb 2022 //
BUSINESSWIRE
JCR Pharma Receives the WORLDSymposium New Treatment Award for IZCARGO
03 Feb 2022 //
BUSINESSWIRE
JCR Pharmaceuticals to Present at the 18th Annual WORLDSymposiumTM 2022
03 Feb 2022 //
BUSINESSWIRE
USFDA grants Fast Track Designation for JR-171
05 Oct 2021 //
CHEMDIV
Takeda and JCR Pharmaceuticals partner to market Hunter syndrome therapy
01 Oct 2021 //
PHARMACEUTICAL-TECHNOLOGY
Takeda Collaboration with JCR Pharmaceuticals
30 Sep 2021 //
BUSINESSWIRE
JCR Pharmaceuticals Announces Approval of IZCARGO®
23 Mar 2021 //
BUSINESSWIRE
JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa)
23 Mar 2021 //
BUSINESSWIRE
JCR Pharmaceuticals Announces Discontinuation of Development of JR-031EB
08 Mar 2021 //
MARKET SCREENER
Japan`s JCR Pharma to build new plant to produce COVID-19 vaccine solution
04 Mar 2021 //
REUTERS
JCR Presents Research at WORLDSymposium 2021 Showing Benefits of JR-141
16 Feb 2021 //
FIRSTWORDPHARMA
AstraZeneca to ask Japan`s JCR Pharmaceutical to produce COVID-19 vaccine
27 Jan 2021 //
REUTERS
JCR Announces First Patient Dosed in Phase1?2 Global TRIAL
30 Oct 2020 //
MINKABU
PHC and JCR Offer Growth Hormone Application for Use in Clinical Research
15 Sep 2020 //
PHCHD
?JCR Pharma : Announces Completion of the Ph1/2 Trial Notification of JR-171
31 Jul 2020 //
MARKETSCREENER
JCR Pharmaceuticals announces Completion of Acquisition of ArmaGen, Inc.
27 Apr 2020 //
PR NEWSWIRE
